image
Healthcare - Medical - Diagnostics & Research - NASDAQ - IE
$ 198.11
-2.15 %
$ 16.4 B
Market Cap
22.04
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one ICLR stock under the worst case scenario is HIDDEN Compared to the current market price of 198 USD, ICON Public Limited Company is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one ICLR stock under the base case scenario is HIDDEN Compared to the current market price of 198 USD, ICON Public Limited Company is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one ICLR stock under the best case scenario is HIDDEN Compared to the current market price of 198 USD, ICON Public Limited Company is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
8.12 B REVENUE
4.89%
956 M OPERATING INCOME
20.23%
612 M NET INCOME
21.18%
1.16 B OPERATING CASH FLOW
106.11%
-227 M INVESTING CASH FLOW
-55.38%
-844 M FINANCING CASH FLOW
2.33%
2.03 B REVENUE
-4.25%
285 M OPERATING INCOME
1.05%
197 M NET INCOME
34.18%
403 M OPERATING CASH FLOW
86.07%
-124 M INVESTING CASH FLOW
-266.73%
-97.8 M FINANCING CASH FLOW
-38.87%
Balance Sheet ICON Public Limited Company
image
Current Assets 3.41 B
Cash & Short-Term Investments 380 M
Receivables 2.9 B
Other Current Assets 132 M
Non-Current Assets 13.6 B
Long-Term Investments 46.8 M
PP&E 502 M
Other Non-Current Assets 13 B
Current Liabilities 2.83 B
Accounts Payable 132 M
Short-Term Debt 147 M
Other Current Liabilities 2.55 B
Non-Current Liabilities 4.92 B
Long-Term Debt 3.79 B
Other Non-Current Liabilities 1.13 B
EFFICIENCY
Earnings Waterfall ICON Public Limited Company
image
Revenue 8.12 B
Cost Of Revenue 5.72 B
Gross Profit 2.4 B
Operating Expenses 1.44 B
Operating Income 956 M
Other Expenses 344 M
Net Income 612 M
RATIOS
29.56% GROSS MARGIN
29.56%
11.78% OPERATING MARGIN
11.78%
7.54% NET MARGIN
7.54%
6.63% ROE
6.63%
3.60% ROA
3.60%
7.21% ROIC
7.21%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ICON Public Limited Company
image
Net Income 612 M
Depreciation & Amortization 586 M
Capital Expenditures -141 M
Stock-Based Compensation 55.7 M
Change in Working Capital -115 M
Others 71.1 M
Free Cash Flow 1.02 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ICON Public Limited Company
image
Wall Street analysts predict an average 1-year price target for ICLR of $362 , with forecasts ranging from a low of $295 to a high of $390 .
ICLR Lowest Price Target Wall Street Target
295 USD 48.91%
ICLR Average Price Target Wall Street Target
362 USD 82.52%
ICLR Highest Price Target Wall Street Target
390 USD 96.86%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership ICON Public Limited Company
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference. businesswire.com - 1 week ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Icon Public Limited Company - ICLR NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Icon Public Limited Company ("ICON" or the "Company") (NASDAQ:ICLR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 2 weeks ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Icon Public Limited Company - ICLR NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Icon Public Limited Company ("ICON" or the "Company") (NASDAQ:ICLR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 2 weeks ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company - ICLR NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Icon Public Limited Company ("ICON" or the "Company") (NASDAQ:ICLR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 3 weeks ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company. - ICLR NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Icon Public Limited Company ("ICON" or the "Company") (NASDAQ:ICLR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 3 weeks ago
ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. On TIME Magazine's 2024 list of World's Best Companies ICON was ranked as the highest clinical research organisation out of 1,000 companies for the second year in a row, and in its 2025 list of World's Best Companies in Sustainable Growth it was featured at number 57 out of 500 companies. ICON was also an. businesswire.com - 3 weeks ago
ICON Public Limited Company (ICLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR. accesswire.com - 4 weeks ago
New Strong Sell Stocks for December 20th ICLR, BHP and CR have been added to the Zacks Rank #5 (Strong Sell) List on December 20, 2024. zacks.com - 4 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages ICON Public Limited Company (ICLR) Shareholders to Inquire about Securities Investigation NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR. accesswire.com - 1 month ago
ICON Stockholders: Robbins LLP is Investigating the Officers and Directors of Icon Energy Corp. to Determine if They Breached Fiduciary Duties Owed to Shareholders SAN DIEGO , Dec. 18, 2024 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Icon Energy Cop. (NASDAQ: ICON) to determine whether certain Icon Energy Corp. officers and directors violated securities laws and breached fiduciary duties to shareholders. prnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating ICON Public Limited Company (ICLR) And Encourages Shareholders to Connect NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company ("ICON" or "the Company") (NASDAQ:ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ICLR. accesswire.com - 1 month ago
ICON Announces Appointment of Chief Operating Officer DUBLIN--(BUSINESS WIRE)--ICON Announces Appointment of Chief Operating Officer. businesswire.com - 1 month ago
8. Profile Summary

ICON Public Limited Company ICLR

image
COUNTRY IE
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 16.4 B
Dividend Yield 0.00%
Description ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Contact South County Business Park, Dublin, 18 https://www.iconplc.com
IPO Date May 15, 1998
Employees 42250
Officers Mr. Diarmaid Cunningham Chief Administrative Officer, General Counsel & Company Secretary Ms. Niamh Murphy Director of Corporate Communications Mr. David Green Vice President of Marketing Mr. Joe Cronin Chief Human Resources Officer Mr. Nigel Clerkin A.C.A. Chief Financial Officer Mr. Barry Balfe Chief Operating Officer Mr. Thomas N. O'Leary Chief Information Officer Mr. Jonathan Andrew Curtain A.C.A. Senior Vice President of Corporate & Commercial Finance Dr. Steven A. Cutler MBA, Ph.D. Chief Executive Officer & Director Dr. John Climax Ph.D. Founder & Independent Non-Executive Director